GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novartis AG (STU:NOTA) » Definitions » Cyclically Adjusted PS Ratio

Novartis AG (STU:NOTA) Cyclically Adjusted PS Ratio : 4.38 (As of May. 23, 2024)


View and export this data going back to . Start your Free Trial

What is Novartis AG Cyclically Adjusted PS Ratio?

As of today (2024-05-23), Novartis AG's current share price is €93.40. Novartis AG's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was €21.33. Novartis AG's Cyclically Adjusted PS Ratio for today is 4.38.

The historical rank and industry rank for Novartis AG's Cyclically Adjusted PS Ratio or its related term are showing as below:

STU:NOTA' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 2.81   Med: 3.7   Max: 4.52
Current: 4.45

During the past years, Novartis AG's highest Cyclically Adjusted PS Ratio was 4.52. The lowest was 2.81. And the median was 3.70.

STU:NOTA's Cyclically Adjusted PS Ratio is ranked worse than
77.96% of 744 companies
in the Drug Manufacturers industry
Industry Median: 2.12 vs STU:NOTA: 4.45

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Novartis AG's adjusted revenue per share data for the three months ended in Mar. 2024 was €5.423. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €21.33 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Novartis AG Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Novartis AG's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novartis AG Cyclically Adjusted PS Ratio Chart

Novartis AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.28 3.98 3.84 3.88 4.09

Novartis AG Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.85 4.11 4.28 4.09 4.17

Competitive Comparison of Novartis AG's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - General subindustry, Novartis AG's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novartis AG's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Novartis AG's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Novartis AG's Cyclically Adjusted PS Ratio falls into.



Novartis AG Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Novartis AG's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=93.40/21.33
=4.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novartis AG's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Novartis AG's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=5.423/107.3549*107.3549
=5.423

Current CPI (Mar. 2024) = 107.3549.

Novartis AG Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 4.155 101.517 4.394
201409 4.195 101.247 4.448
201412 4.406 100.704 4.697
201503 4.609 100.339 4.931
201506 4.688 100.464 5.010
201509 4.563 99.785 4.909
201512 4.857 99.386 5.246
201603 4.423 99.475 4.773
201606 4.700 100.088 5.041
201609 4.580 99.604 4.936
201612 4.992 99.380 5.393
201703 4.612 100.040 4.949
201706 4.686 100.285 5.016
201709 4.514 100.254 4.834
201712 2.304 100.213 2.468
201803 3.857 100.836 4.106
201806 4.252 101.435 4.500
201809 4.174 101.246 4.426
201812 4.467 100.906 4.752
201903 4.334 101.571 4.581
201906 4.561 102.044 4.798
201909 4.934 101.396 5.224
201912 4.961 101.063 5.270
202003 5.018 101.048 5.331
202006 4.479 100.743 4.773
202009 4.624 100.585 4.935
202012 4.689 100.241 5.022
202103 4.708 100.800 5.014
202106 4.887 101.352 5.176
202109 5.041 101.533 5.330
202112 1.811 101.776 1.910
202203 5.201 103.205 5.410
202206 5.599 104.783 5.736
202209 4.996 104.835 5.116
202212 4.797 104.666 4.920
202303 4.867 106.245 4.918
202306 6.140 106.576 6.185
202309 5.460 106.570 5.500
202312 5.207 106.461 5.251
202403 5.423 107.355 5.423

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Novartis AG  (STU:NOTA) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Novartis AG Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Novartis AG's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Novartis AG (STU:NOTA) Business Description

Industry
Address
Lichtstrasse 35, Basel, CHE, 4056
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Novartis AG (STU:NOTA) Headlines

No Headlines